DE69233255T2 - Carbamatanalogen von thiaphysovenin, pharmazeutische zusammensetzungen und verfahren zur hemmung von cholinesterasen - Google Patents

Carbamatanalogen von thiaphysovenin, pharmazeutische zusammensetzungen und verfahren zur hemmung von cholinesterasen Download PDF

Info

Publication number
DE69233255T2
DE69233255T2 DE69233255T DE69233255T DE69233255T2 DE 69233255 T2 DE69233255 T2 DE 69233255T2 DE 69233255 T DE69233255 T DE 69233255T DE 69233255 T DE69233255 T DE 69233255T DE 69233255 T2 DE69233255 T2 DE 69233255T2
Authority
DE
Germany
Prior art keywords
compound
group
racemic
halide
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69233255T
Other languages
German (de)
English (en)
Other versions
DE69233255D1 (de
Inventor
Arnold Brossi
Xiao-Shu He
Stanley I. Rapoport
Nigel H. Greig
Malgarzota Brzostowska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Application granted granted Critical
Publication of DE69233255D1 publication Critical patent/DE69233255D1/de
Publication of DE69233255T2 publication Critical patent/DE69233255T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
DE69233255T 1991-09-26 1992-08-26 Carbamatanalogen von thiaphysovenin, pharmazeutische zusammensetzungen und verfahren zur hemmung von cholinesterasen Expired - Fee Related DE69233255T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US76576691A 1991-09-26 1991-09-26
US765766 1991-09-26
US84508192A 1992-03-03 1992-03-03
US845081 1992-03-03
PCT/US1992/007085 WO1993005779A1 (en) 1991-09-26 1992-08-26 Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases

Publications (2)

Publication Number Publication Date
DE69233255D1 DE69233255D1 (de) 2004-01-08
DE69233255T2 true DE69233255T2 (de) 2004-05-27

Family

ID=27117648

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233255T Expired - Fee Related DE69233255T2 (de) 1991-09-26 1992-08-26 Carbamatanalogen von thiaphysovenin, pharmazeutische zusammensetzungen und verfahren zur hemmung von cholinesterasen

Country Status (10)

Country Link
US (1) US5378723A (enExample)
EP (2) EP0605474B1 (enExample)
JP (1) JP3193717B2 (enExample)
AT (1) ATE254916T1 (enExample)
AU (1) AU667318B2 (enExample)
CA (1) CA2119782C (enExample)
DE (1) DE69233255T2 (enExample)
DK (1) DK0605474T3 (enExample)
ES (1) ES2206449T3 (enExample)
WO (1) WO1993005779A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002154A1 (en) * 1997-07-09 1999-01-21 Axonyx Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
WO2002048150A2 (en) * 2000-11-02 2002-06-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
WO2005074917A1 (en) * 2004-01-30 2005-08-18 Axonyx, Inc. Methods for treatment of complications of diabetes
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR101667215B1 (ko) 2014-10-21 2016-10-18 한밭대학교 산학협력단 신규한 트립타민 컨쥬게이트 화합물 및 그의 용도
KR102233120B1 (ko) 2018-12-18 2021-03-29 한밭대학교 산학협력단 신규한 파에오놀-트립타민 화합물 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133930A (en) * 1961-08-15 1964-05-19 Ciba Geigy Corp Ester and amide derivatives of thieno-[3, 2-b] indole 3-carboxylic acids
US4900748A (en) * 1988-03-04 1990-02-13 The United States Of America As Represented By The Department Of Health And Human Services Carbamates related to (-)-physostigmine as cholinergic agents

Also Published As

Publication number Publication date
JP3193717B2 (ja) 2001-07-30
EP0605474A1 (en) 1994-07-13
AU667318B2 (en) 1996-03-21
EP1251131A3 (en) 2002-10-30
CA2119782C (en) 2005-08-23
EP0605474B1 (en) 2003-11-26
US5378723A (en) 1995-01-03
AU2504292A (en) 1993-04-27
ES2206449T3 (es) 2004-05-16
EP1251131A2 (en) 2002-10-23
CA2119782A1 (en) 1993-04-01
DE69233255D1 (de) 2004-01-08
EP0605474A4 (enExample) 1994-08-03
WO1993005779A1 (en) 1993-04-01
JPH07505120A (ja) 1995-06-08
DK0605474T3 (da) 2004-02-23
ATE254916T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
DE69233093T2 (de) Substituierte phenserine und phenylcarbamate von (-)-eserolin, (-)-n1-noreserolin und (-)-n1-benzylnoresorolin als spezifische acetylcholinesterase-inhibitoren
DE3750596T2 (de) 1,2,3,3a,8,8a-Hexahydro-1,3a,8-Trimethylpyrrolo[2,3-b]indole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
DE69331605T2 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE3687288T2 (de) Chinuclidinderivate.
DE69733478T2 (de) Ether-muskarinantagonisten
DE69031649T2 (de) Oxoindolderivate
DE69031259T2 (de) Mit Physostigmine verwandte N-aminocarbamate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0605474B1 (en) Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases
DE4430091A1 (de) Verwendung von N-substituierten Phenothiazinen
DE69329084T2 (de) Benzoxazepin-Derivate als Cholinesterase-Inhibitoren
EP0288048B1 (de) Benzo- und Thieno-3,4-dihydro-pyridinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2804519C2 (enExample)
DE3854991T2 (de) Cyclische Amine und pharmakologische Verbindungen
DE3503074A1 (de) Hydantoinderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
DE2647041A1 (de) 3-aminomethylen-6,7-dimethoxy-2- methyl-4-oxo-1,2,3,4-tetrahydro-1- chinolincarbonsaeureester und zwischenprodukte zur herstellung derselben
DE3889043T2 (de) N-(substituiertes Alkyliden)-1,2,3,4-tetrahydro-9-acridinamine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US3998843A (en) Quaternary ammonium compounds
EP0124630B1 (de) Pyrimidin-Thioalkylpyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindung enthaltende Arzneimittel
DE2717001A1 (de) Arzneimittel mit antithrombotischer wirkung
DE3223877C2 (enExample)
DD275050A5 (de) Verfahren zur herstellung von 1,3,4,16b-tetrahydro-2h,10h-indde[2,1-c]-pyrazine [1,2-a][1,4]benzodiazepin-derivaten
DE3146867C2 (enExample)
DE69635901T2 (de) Polycyclische derivate
AT395852B (de) Imidazolyl-methyl-tetrahydrothiophenderivate
DE3853895T2 (de) Substituierte 9-Amino-spiro[cycloalkyl[b]chinolin-2,1'cycloalkane], Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee